Table 2. Univariate Analysis of One-year Survival Estimates by Patient and Clinical Characteristics.

Variables	Patients	Events	Median Survival (Month)	1-Year Overall Survival Estimate (95% CI)	P Value
All	47	30	9.8	0.47 (0.31, 0.61)
Age
≤ 35	23	14	13.2	0.50 (0.27, 0.69)
> 35	24	16	8.4	0.44 (0.23, 0.63)	0.43
Gender
Female	30	20	9.8	0.48 (0.29, 0.65)
Male	17	10	10.2	0.45 (0.20, 0.67)	0.46
Performance status (ECOG)
0	11	4	24.8	0.68 (0.31, 0.89)
1–3	32	24	9.5	0.38 (0.21, 0.55)	0.12
Number of metastatic sites
1	11	3	NR	0.78 (0.36, 0.94)
2	12	8	24.8	0.52 (0.21, 0.77)
3+	24	19	8.2	0.32 (0.14, 0.51)	0.0007
Lactate dehydrogenase
Normal	25	14	15.2	0.67 (0.44, 0.83)
High	18	14	6.0	0.21 (0.06, 0.43)	0.004
Neutrophil-lymphocyte ratio
≤ 5	31	18	15.2	0.59 (0.39, 0.75)
> 5	13	10	8.4	0.25 (0.06, 0.50)	0.05
Lung metastasis
No	25	13	14.7	0.64 (0.40, 0.80)
Yes	22	17	8.2	0.28 (0.11, 0.49)	0.016
Liver metastasis
No	29	18	12.1	0.56 (0.35, 0.73)
Yes	18	12	6.0	0.33 (0.13, 0.55)	0.13
Bone metastasis
No	31	18	10.2	0.52 (0.32, 0.69)
Yes	16	12	8.3	0.38 (0.15, 0.61)	0.10
Lymph nodes metastasis
No	19	11	13.2	0.52 (0.26, 0.72)
Yes	28	19	9.3	0.44 (0.24, 0.62)	0.48
First line treatment
5FU based	11	8	10.2	0.43 (0.14, 0.69)
Gemcitabine based	8	3	15.2	0.83 (0.27, 0.97)
Platinum based	14	12	6.0	0.15 (0.02, 0.39)
Surgery + Radiation	8	3	37.7	0.85 (0.30, 0.98)	0.0005
Tissue of origin tested
No	21	16	8.4	0.32 (0.13, 0.52)
Yes	26	14	15.2	0.60 (0.37, 0.77)	0.007